Vesleteplirsen for Duchenne Muscular Dystrophy
(MOMENTUM Trial)
Trial Summary
What is the purpose of this trial?
This trial tests vesleteplirsen, a drug, for safety and tolerance. It involves participants from previous studies and new ones. The goal is to find the highest safe dose and monitor side effects.
Research Team
Medical Director
Principal Investigator
Sarepta Therapeutics, Inc.
Eligibility Criteria
This trial is for individuals with Duchenne Muscular Dystrophy who can potentially benefit from exon 51-skipping treatment. Participants must have previously received SRP-5051 in Part A of this study or in Study 5051-102 to be eligible.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Part A: Multiple Ascending Dose
Participants receive escalating dose levels of vesleteplirsen every 4 weeks via IV infusion to determine the maximum tolerated dose
Part B: Dose Expansion
Participants receive vesleteplirsen at doses selected from Part A every 4 weeks via IV infusion
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- SRP-5051
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sarepta Therapeutics, Inc.
Lead Sponsor